Fertility drugs are one of the main treatments for women who are infertile due to ovulation disorders and are used to stimulate a woman's eggs better or to produce extra eggs. Most fertility drugs work like natural hormones to ensure the main gonads in the ovaries function normally.

In an attempt to find more effective drugs for female infertility, researchers at Imperial College London University in Britain have developed a new drug that can improve fertility in women with reproductive health problems [1].

The researchers added in their study, published in the latest issue of the Journal of Clinical Investigation, that the drug called (MVT-602) focuses mainly on treating the problem of Polycystic Ovary Syndrome (PCOS), a common hormonal disorder that affects how a woman's ovaries work. And it leads to irregular menstrual problems [2].

The treatment targets hypothalamic menopause (HA), a condition in which menstruation stops for several months due to a problem in the hypothalamus in the centre of the brain that controls reproduction, where the gonadotrophin-releasing hormone (GnRH) is produced, which plays a key role in stimulating the pituitary gland. On the production of other natural hormones required for egg maturation and ovulation, such as follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which send signals to the ovaries to produce oestrogen, which regulates the flow and thickness of the uterine mucous secretions, in addition to enhancing the movement of sperm into the egg and helps fertilisation. To the hormone progesterone, which prepares the uterus for a fertilized egg [3].

Infertility affects about 15% of couples around the world and women's reproductive health problems stop nearly half of spouses' reproductive failure cases. In the United States alone, about 12% of women between the ages of 15 and 44 have difficulty conceiving or getting pregnant to term [4].

Kisspeptin, which is made in the hypothalamus of the brain, is an important hormone for the production of many other hormones. It is associated with puberty, enters receptor sites in the pituitary gland and initiates a reaction that causes the gland to secrete neurotransmitters that contribute to the release of the hormones (FSH) and (LH). And insufficient function of this hormone can lead to infertility, by preventing the menstrual cycle in women [5].

During the past years, scientists have reached the natural form of kisspeptin, which is called "kespeptin-54" (KP54) and it was produced in the form of an injection to treat women with reproductive disorders, but it requires high doses to give good results, but the research team developed its new drug to achieve better results than an injection of natural " kespeptin-54" at a lower dose.

A study points out that the hormone "kisspeptin" is naturally secreted in the body in healthy women, through the axis of the hypothalamic region and thus the menstrual cycle and ovulation process are regularized, but in contrast So, women with polycystic ovary syndrome or hypothalamic amenorrhea (HA) suffer from an imbalance in (hypothalamic) and this results in the rapid breakdown of the hormone "kisspeptin", so they are resorted to giving them this hormone in the form of injections (KP54) for regularity of work [4,6].

Delayed childbearing is a social, medical and economic problem that burdens the Arab region and is a concern in family life. There are several causes of delayed fertility in women, including:

• Uterine-related causes: such as narrowing of the cervix and cervical ulcers and birth defects of the uterus such as a uterus with two horns or a septum

• Causes associated with the fallopian tubes: these are channels that capture the egg through the so-called cilia, inside which the egg is captured by the sperm and these channels can be susceptible to microbial infections such as tuberculosis or chlamydia and the organ leads to a blockage of the ducts and an inability to efficiently discharge its function

• Causes related to the ovaries: The ovaries are those that produce eggs and the hormonal axis, which consists of the pituitary gland in the brain, the thyroid gland and the end of the ovaries, regulates the secretion and functioning of the hormones in charge for regularity of ovulation and cycle and stimulation of the endometrium for the onset of pregnancy

As for other causes, which have become the main factor that must be carefully studied and diagnosed in order to identify the direct causes of delayed childbirth, these are factors associated with the endocrine glands that secrete hormones, namely the pituitary gland, the thyroid gland and the disorder of the hormone prolactin "milk” as well as some common causes such as obesity and general weakness. We will look at some of the endocrine issues that directly affect the regularity of the cycle and ovulation and can also lead to delayed childbirth. The pituitary gland sometimes generates some women and they have insufficient activity in the secretion of pituitary hormones, so they do not secrete hormones normally, so the ovaries are not stimulated or not stimulated normally and therefore the patient does not have a menstrual cycle. Some women may also experience a very severe case of uterine bleeding for one reason or another. After childbirth, if the situation is not corrected and the cause of the bleeding is eliminated quickly, heavy bleeding can lead to a decrease in the amount of blood supplying the pituitary gland and this gland, as we mentioned earlier, controls the woman's fertility and her injury, with any damage, will inevitably lead to infertility. the patient as a result of a lack of hormones that she secretes, which in turn control functions as important and important as ovulation. Thyroid: The thyroid gland is located in the front of a person's neck and is responsible for the secretion of thyroxine, a hormone based on iodine and if this gland does not function regularly due to insufficient secretion or due to its excessive secretion, it leads in both cases to irregular ovulation and a serious cycle violation occurs. In the form of frequent bleeding followed by a complete cessation of the menstrual cycle or in the form of immediate menopause, along with many other symptoms such as a significant change in weight with hair loss and abnormalities in the percentage of lipids in the blood, thyroid disease and then menstrual irregularity in the first stage diseases [1,5,7].

The physician and patient may not notice the simplicity of the symptoms, knowing that the condition is diagnosed simply through blood tests and that treatment is also available and simple through certain medications and in some cases, surgery may be required to remove part of the thyroid gland.

Type of Treatment 

A low-calorie diet with satisfactory nourishing admission and quality food choices improved ripeness results in PCOS by altogether improving insulin affectability. A randomized controlled preliminary (RCT) by Mehrabani et al. and a methodical audit by Moran et al. on wholesome organization in the treatment of PCOS, discovered improvement in feminine routineness, more prominent decrease in insulin opposition and aggregate and high-thickness lipoproteins with diminished sugars and decreased glycaemic list, improved gloom and confidence were seen on a high protein diet. Diminished insulin opposition likewise lessens dangers, for example, type 2 diabetes, dyslipidaemia and coronary illness in the long haul. Existing proof backings the advantages of a solid eating regimen. Fundamentally an eating routine that is moderate in starches, wealthy in fibre, moderate comparable to polyunsaturated and monounsaturated fats, with a more prominent extent of lean protein sources, prescribed and to get the most extreme advantages, it is imperative to follow good food designs which are: Take little segments at continuous stretches [8]. The current proposals for weight reduction for the individuals who are overweight, mean to accomplish an energy shortage of 30% or from 500 to 750 kcal/day (1200-1500 kcal/day) and techniques for accomplishing higher than the eating regimen ought to be defined and arranged [9]. 

Expanded weight list (BMI) or other clinical highlights of PCOS, for example, hirsutism can seriously influence self-perception. Self-perception trouble is related with wretchedness. Depression can influence the inspiration needed for self-care endeavours contrarily and can grow further because of many incessant undesirable encounters or bombed endeavours to improve the way of life. 

Satisfactory treatment for despondency improves PCOS side effects of self-insight and personal satisfaction (QOL) brokenness. What's more, treatment of PCOS clinical manifestations may improve indications of misery. Pharmacotherapy and psychotherapy are both viable treatment modalities for burdensome indications and proof backings the joined methodology as the best. Thus, recognizing female with trouble and wretchedness is vital and the presentation of focused treatments like intellectual conduct treatment to alleviate sadness and improve QOL ought to be thought of [10]. 

An assortment of cross-sectional test upholds the positive consequences of activity on the psychological well-being of female with PCOS. Liao et al. showed that a 6-month energetic strolling project can fundamentally decrease self-perception unsettling influence, in spite of the fact that there was no adjustment in BMI in these patients. In this examination, 35 females with a BMI ⩾25 kg/m2 took an interest. Some 23 returned following a half year for re-assessment. Of these, 12 of them finished the activity program. Pre-assessment and post-assessment showed a huge decrease in self-perception trouble to supplementation (p <0.01) albeit no huge change in BMI was found. Since the quantity of members was low, suggestions for RCT were made [11].

The principle of pharmacological fertility treatment in women with PCOS is the treatment of anovulation where PCOS accounts for 80% of WHO type 2 infertility.

Drug Medicine

Clomiphene is a sterility prescription that can build the quantity of develop eggs for conceivable treatment. It is utilized by ladies who don't ovulate sporadically and by ladies who don't ovulate however have not been effective in getting pregnant. Clomiphene citrate doesn't seem to improve the probability of pregnancy in ladies who ovulate consistently yet neglect to imagine following a year or a greater amount of unprotected intercourse and are thusly viewed as fruitful. The risk associated with clomiphene citrate treatment is a 10% chance of a multiple pregnancy The results of this review of trials should be used with caution due to the heterogeneity of these studies [7,9,11,12].

Clomiphene citrate is a sterility medication that can increase the number of mature eggs for possible fertilisation. It is used by women who do not ovulate irregularly and by women who do not ovulate but have not been successful in getting pregnant. Clomiphene citrate does not appear to increase the likelihood of pregnancy in women who ovulate regularly but fail to conceive after a year or more of unprotected intercourse and are therefore considered fertile. The risk associated with clomiphene citrate treatment is a 10% chance of a multiple pregnancy. The results of this review of trials should be used with caution due to the heterogeneity of these studies.

We found evidence indicating that clomiphene citrate increases the chances of a clinical pregnancy compared to a placebo [13].

We found no evidence of a difference between clomiphene and tamoxifen, which is a similar anti-oestrogen drug. Women treated with clomiphene citrate were less likely to become pregnant or have a baby alive than women who received gonadotropins; No evidence was found for difference in the chances of a multiple pregnancy. The number of women who became pregnant in these trials was very small, so we cannot be completely certain of these results [14].

Dexamethasone (a steroid) and combined oral contraceptives are used in addition to clomiphene, which gives hope for good results, but more research is needed to confirm this. Several studies reported results that went beyond early detection of pregnancy; Given the reported risks of miscarriage when using clomiphene, it is not possible to draw definitive conclusions about effective treatment. We found evidence indicating that a 10-day regimen of clomiphene citrate increases the chances of conception compared to the 5-day regimen, although data is limited and more research is needed. Insufficient data were provided to compare short- and long-term regimens with clomiphene citrate [13,15].

Letrozole, a potent third-generation oral aromatase inhibitor and reversible (AI), is widely used to treat postmenopausal women with metastatic breast cancer Such treatment, usually performed at a dose of 2.5-5.0 mg / day, allows to achieve optimal inhibition of oestrogen levels in the blood and is virtually devoid of side effects [1,2]. Letrozole's oestrogen-lowering property can be used to effectively neutralize the estrogenic effect through the mechanism of adverse reactions on the hypothalamus and thus stimulate the secretion of follicle-stimulating hormone (FSH) When taken orally in doses of 1-5 mg / day, letrozole and anastrozole reduce oestrogen levels by 97-99% [3]. Due to the significant decrease in the level of oestrogen in the peripheral blood, artificial intelligence is a promising method for treating not only oestrogen-dependent diseases, but also its use in the early follicular stage of the menstrual cycle can increase the pituitary secretion of gonadotropic hormones to the growth of follicles and ovulation in infertile patients. Although letrozole is widely used as an ovulation inducer, it is still off-label [16].

For a long time, clomiphene citrate (CC) has been used as a first-line drug to treat patients with polycystic ovary syndrome (PCOS). The main disadvantages of using CC are the following: CC blocks oestrogen receptors (ER) throughout the body, while reducing endometrial receptivity, has a long half-life and has cumulative properties. Over the past fifteen years, since the first few publications, Letrozole has been widely accepted as an ovulation inducer. Numerous original articles, reviews and meta-analysis have been published on the topic. Especially in women with failed attempts or CC resistance, Letrozole has been shown to be very effective in terms of ovulation rate and live birth rate [15,17].

A precise audit including 7 randomized controlled preliminaries contrasting CC and letrozole in female with PCOS. A meta-examination showed a fundamentally higher pregnancy rate and live birth rate per patient for letrozole contrasted with CC. Overall, these investigations represented 1833 patients (906 in the letrozole gathering and 927 in the CC gathering) and 4999 ovulation enlistment cycles (2455 in the letrozole gathering and 2544 in the CC gathering). Five of the included examinations detailed information on the live birth rate. There was a measurably huge expansion in the paces of live birth and pregnancy in the letrozole bunch contrasted with the CC gathering (hazard proportion, RR = 1.55, 95% CI: 1.26-1.90 and RR = 1.38, 95% CI: 1.05-1.83) for the paces of live births and pregnancy, straight [18].

In vitro Fertilisation

IVF (in vitro fertilisation) is an assisted reproductive technology used when a normal pregnancy is impossible. This method is relatively simple, its theory is developed to the smallest detail and its application gives very high results. Around the world, IVF is the main method of treating infertility. It is effective in all forms. Additionally, IVF is often the only way out for families where a man becomes ill. The success rate of this procedure is about 30-35% [9,12].

The essence of this method to overcome infertility is that the fertilisation process takes place outside the mother's body. First, the woman is prepared with special preparations to obtain mature female reproductive cells (stimulation of ovulation). Then, under ultrasound control, they are removed (punctured) from the ovaries and then, under laboratory conditions, the eggs are combined with the sperm in a test tube (fertilisation). As a result, embryos are obtained that grow in a special environment and are then transferred (implanted) into the woman's uterus. The final stage, subject to a positive result, is the beginning of the long-awaited pregnancy. Given the fact that many eggs are involved in the IVF attempt, there are often cases where it turns out that multiple pregnancies [15-18].

Violation of the production of sex hormones in the ovaries leads to a decrease in oestrogen levels. As a result, menstruation becomes scarce until it is completely gone. In some cases, on the contrary, uterine bleeding is observed due to the process of hyperplasia formed by the endometrium.

Polycystic ovary disorder is a diverse condition. Henceforth, while picking a successful treatment alternative for a lady with PCOS, a thorough methodology assumes a significant part. Multidisciplinary care tends to disabled fruitfulness or ovulation, yet additionally metabolic and mental issues that are frequently connected with their extension. Complete consideration empowers clinicians to try not to botch any chance for anticipation, treatment and wellbeing improvement, to forestall future intricacies and increment achievement paces of fruitfulness medicines.

1. Weiss, N.S. et al. “Gonadotrophins for ovulation induction in women with polycystic ovarian syndrome.” Cochrane Database of Systematic Reviews, no. 9, 2015. https://doi.org/10.1002/14651858.CD010290.pub2.

2. Farquhar, C. et al. “Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome.” Cochrane Database of Systematic Reviews, no. 6, 2012. https://doi.org/10.1002/14651858. CD001122.pub4.

3. Cleemann, L. et al. “Laparoscopic ovarian drilling as first line of treatment in infertile women with polycystic ovary syndrome.” Gynecological Endocrinology, vol. 18, no. 3, 2004, pp. 138-143.

4. Amer, S.A.K. et al. “A prospective dose-finding study of the amount of thermal energy required for laparoscopic ovarian diathermy.” Human Reproduction, vol. 18, no. 8, 2003, pp. 1693-1698.

5. Siristatidis, C.S. et al. “In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction.” Cochrane Database of Systematic Reviews, no. 11, 2018. https://doi.org/10.1002/146518 58.CD006606.pub.

6. Tso, L.O. et al. “Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome.” Cochrane Database of Systematic Reviews, no. 12, 2020.

7. Youssef, M.A. et al. “Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.” Cochrane Database of Systematic Reviews, no. 1, 2011.

8. Gremeau, A.S. et al. “In vitro maturation or in vitro fertilisation for women with polycystic ovaries? A case-control study of 194 treatment cycles.” Fertility and Sterility, vol. 98, no. 2, 2012, pp. 355-360.

9. Pundir, J. et al. “Meta-analysis of GnRH antagonist protocols: do they reduce the risk of OHSS in PCOS?” Reproductive Biomedicine Online, vol. 24, no. 1, 2012, pp. 6-22.

10. Basatemur, E. and A. Sutcliffe. “Health of IVM children.” Journal of Assisted Reproduction and Genetics, vol. 28, no. 6, 2011, pp. 489-493.

11. Human Fertilisation and Embryology Authority. “Our campaign to reduce multiple births.” Human Fertilisation and Embryology Authority, https://www.hfea.gov.uk/ about-us/our-campaign-to-reduce-multiple-births/.

12. Bayram, N. et al. “Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: randomized controlled trial.” BMJ, vol. 328, no. 7433, 2004, p. 192.

13. Soohie, G.A. et al. “In vitro maturation or in vitro fertilisation for women with polycystic ovaries? A case control study of 194 treatment cycles.” Fertility and Sterility, vol. 98, 2012, pp. 335-336.

14. Child, T.J. et al. “A comparison of in vitro maturation and in vitro fertilisation for women with polycystic ovaries.” Obstetrics and Gynecology, vol. 100, no. 4, 2002, pp. 665-670.

15. Teede, H.J. et al. “Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.” Human Reproduction, vol. 33, no. 9, 2018, pp. 1602-1618.

16. Tannus, S. et al. “Predictive factors for live birth after in vitro maturation of oocytes in women with polycystic ovary syndrome.” Archives of Gynecology and Obstetrics, vol. 297, no. 1, 2018, pp. 199-204.

17. Hashim, H.A. et al. “Laparoscopic ovarian diathermy after clomiphene failure in polycystic ovary syndrome: is it worthwhile? A randomized controlled trial.” Archives of Gynecology and Obstetrics, vol. 284, no. 5, 2011, pp. 1303-1309.

18. Balen, A. “Surgical treatment of polycystic ovary syndrome.” Best Practice and Research Clinical Endocrinology and Metabolism, vol. 20, no. 2, 2006, pp. 271-280.